Hematología y Hemoterapia

Resultados: 392
Tipo Título / Nombre Autor(es) Año
Characteristics and treatment strategies of Secondary Acute Myeloid Leukemia Patients: Data from the PETHEMA AML epidemiological registry Martínez-Cuadrón D, Serrano J, Martínez O, Pérez-Simón JA, Gil C ..., Bergua JM, et al 2020
Bispecific T cell engager antibodies may contribute to reactivate pre-existing tumor specific T cells Primo D, Pérez Oteyza J, Bergua JM, Hernández Rivas JA, Ruiz E, Vives S, et al 2020
The mode of action (MOA) of the anti-CD38 monoclonal antibody (MAB) Isatuximab in elderly acute myeloid leukemia Zabaleta A, Alameda D, Ajona C, Perez C, Alignani D, ..., et al 2020
Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352] Rodríguez-Medina C, Martínez-Cuadrón D, Cano I, Gil C, Tormo M..., Bergua-Burgues JM, et al 2020
Lenalidomida + R-GDP (R2-GDP) en linfoma b difuso de células grandes refractario o en recaída. Resultados finales del ensayo R2-GDP-GOTEL Espejo García P, Martin García A, Palazón Carrión N, Nogales Fernández E, Carnicero González F, Rios Herranz E, et al 2020
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project Sargas C, Ayala R, Chillón MC, Larráyoz MJ, Carrillo-Cruz E..., Bergua J, et al 2020
Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry Martínez P, Palanques Pastor T, López Lorenzo JL, Cornago Navascués J, Rodríguez Macías G, Cano I, et al 2020
Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry Labrador J, Martínez Cuadrón D, Fuente A de la, Rodríguez Veiga R, Serrano J, Tormo M, et al 2020
Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates Martínez López J, Montesinos P, Martínez Sánchez P, Gorrochategui J, Rojas JL, Prino D, et al 2020
Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial Simoes CP, Paiva B, Martínez Cuadron D, Bergua JM, Vives S, Algarra JL, et al 2020